Drug Profile
DRGT 111
Alternative Names: DRGT111Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Pain in Hungary
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 16 May 2017 Preclinical trials in Pain in Hungary before May 2017 (Druggability Technologies pipeline, May 2017)